NEW YORK, NY / ACCESSWIRE / March 19, 2015 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer , David Mazzo. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his first blog as CEO, Mr. Mazzo writes of his excitement regarding NeoStem's "prospects to bring paradigm-changing new therapies to bear on diseases with high unmet medical need." Mr. Mazzo reviews the Company's advancement plans for NBS20, NBS10 and NBS03D and shares why he remains confident in NeoStem's future, both financially and scientifically. Read the full blog post from Mr. Mazzo on TheChairmansBlog.com (http://www.thechairmansblog.com/neostem/david-mazzo/ceo-letter-neostem-shareholders/).

About NeoStem, Inc.

NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell based personalized medicine therapeutics that prevent, treat or cure disease. The Company is developing therapies based on three platform technologies (immune-oncology, ischemic repair and immunomodulation) with a lead, late-stage (Phase 3, 2 and 2, respectively) clinical program for each. The combination of a rich therapeutics pipeline and an externally recognized in-house center for cell therapy process development and manufacturing has created an organization with unique capabilities for accelerated and efficient product development. www.neostem.com.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com.

SOURCE: The Chairman's Blog